A double-blind, placebo-controlled, dose ranging phase II study to determine the lowest effective dose of ATB-346 for osteoarthritis

Next Previous
Trial Profile

A double-blind, placebo-controlled, dose ranging phase II study to determine the lowest effective dose of ATB-346 for osteoarthritis

Planning
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs ATB 346 (Primary)
  • Indications Pain
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Apr 2017 According to an Antibe Therapeutics media release, this trial is expected to be completed by the end of Q2 2018.
    • 29 Nov 2016 According to an Antibe Therapeutics media release, this trial is expected to initiate in 2017.
    • 09 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top